The DOI matches its Crossref record; 126 of the 126 references it cites were found in a registry or an index.
Histone Deacetylase Inhibitors in Cancer Therapy
Abstract
Purpose: Epigenetic processes are implicated in cancer causation and progression. The acetylation status of histones regulates access of transcription factors to DNA and influences levels of gene expression. Histone deacetylase (HDAC) activity diminishes acetylation of histones, causing compaction of the DNA/histone complex. This compaction blocks gene transcription and inhibits differentiation, providing a rationale for developing HDAC inhibitors. Methods: In this review, we explore the biology of the HDAC enzymes, summarize the pharmacologic properties of HDAC inhibitors, and examine results of selected clinical trials. We consider the potential of these inhibitors in combination therapy with targeted drugs and with cytotoxic chemotherapy. Results: HDAC inhibitors promote growth arrest, differentiation, and apoptosis of tumor cells, with minimal effects on normal tissue. In addition to decompaction of the histone/DNA complex, HDAC inhibition also affects acetylation status and function of nonhistone proteins. HDAC inhibitors have demonstrated antitumor activity in clinical trials, and one drug of this class, vorinostat, is US Food and Drug Administration approved for the treatment of cutaneous T-cell lymphoma. Other inhibitors in advanced stages of clinical development, including depsipeptide and MGCD0103, differ from vorinostat in structure and isoenzyme specificity, and have shown activity against lymphoma, leukemia, and solid tumors. Promising preclinical activity in combination with cytotoxics, inhibitors of heat shock protein 90, and inhibitors of proteasome function have led to combination therapy trials. Conclusion: HDAC inhibitors are an important emerging therapy with single-agent activity against multiple cancers, and have significant potential in combination use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919 · cited 4×
“Further work has identified at least 18 human HDACs, with varying function, localization, and substrates (Table 1).(16,17) The four classes of HDACs are grouped by their homology to yeast proteins.”
BackgroundInfluentialActivation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559
HSP90 and the chaperoning of cancer
Whitesell, L., & Lindquist, S. L. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1716 · Cited by 2,502
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Fraga, M. F., Ballestar, E., Villar-Garea, A., Boix-Chornet, M., Espada, J., Schotta, G., Bonaldi, T., Haydon, C., Ropero, S., Petrie, K., et al. (2005) · Nature Genetics · doi:10.1038/ng1531 · Cited by 1,923
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“In vitro and in vivo, HDAC inhibitors cause cell cycle arrest and differentiation of many tumor types, including breast cancer.(61) However, in a study of invasive breast cancer, increased HDAC1 and 3 expression was paradoxically correlated with improved disease-free survival.”
BackgroundRoth, S. Y., Denu, J. M., & Allis, C. D. (2001) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.70.1.81 · Cited by 1,845
A Mammalian Histone Deacetylase Related to the Yeast Transcriptional Regulator Rpd3p
Taunton, J., Hassig, C. A., & Schreiber, S. L. (1996) · Science · doi:10.1126/science.272.5260.408 · Cited by 1,829
Cited by
Cell-free nucleic acids as biomarkers in cancer patients
Schwarzenbach, H., Hoon, D. S. B., & Pantel, K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3066 · Cited by 2,891
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.-P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.013 · Cited by 1,694
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Curcumin—From Molecule to Biological Function
Esatbeyoglu, T., Huebbe, P., Ernst, I. M. A., Chin, D., Wagner, A. E., & Rimbach, G. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201107724 · Cited by 904
Serrano-Gomez, S. J., Maziveyi, M., & Alahari, S. K. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0502-x · Cited by 814
Epigenetic modifications as therapeutic targets
Kelly, T. K., De Carvalho, D. D., & Jones, P. A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1678 · Cited by 793
Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents
Mottamal, M., Zheng, S., Huang, T., & Wang, G. (2015) · Molecules · doi:10.3390/molecules20033898 · Cited by 680
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
O'Connor, O. A., Horwitz, S., Masszi, T., Van Hoof, A., Brown, P., Doorduijn, J., Hess, G., Jurczak, W., Knoblauch, P., Chawla, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.2782 · Cited by 555
Epigenetics in cancer stem cells
Toh, T. B., Lim, J. J., & Chow, E. K.-H. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0596-9 · Cited by 422
Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy
Cao, D. J., Wang, Z. V., Battiprolu, P. K., Jiang, N., Morales, C. R., Kong, Y., Rothermel, B. A., Gillette, T. G., & Hill, J. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015081108 · Cited by 405
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Pandey, K., An, H., Kim, S. K., Lee, S. A., Kim, S., Lim, S. M., Kim, G. M., Sohn, J., & Moon, Y. W. (2019) · International Journal of Cancer · doi:10.1002/ijc.32020 · Cited by 361
Role of integrated cancer nanomedicine in overcoming drug resistance
Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.012 · Cited by 343
The future of epigenetic therapy in solid tumours—lessons from the past
Azad, N., Zahnow, C. A., Rudin, C. M., & Baylin, S. B. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.42 · Cited by 335
Holbeck, S. L., Collins, J. M., & Doroshow, J. H. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0106 · Cited by 311
Mahalingam, D., Mita, M., Sarantopoulos, J., Wood, L., Amaravadi, R. K., Davis, L. E., Mita, A. C., Curiel, T. J., Espitia, C. M., Nawrocki, S. T., et al. (2014) · Autophagy · doi:10.4161/auto.29231 · Cited by 285
Regulation of the latent-lytic switch in Epstein–Barr virus
Kenney, S. C., & Mertz, J. E. (2014) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2014.01.002 · Cited by 281
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?
Baig, S., Seevasant, I., Mohamad, J., Mukheem, A., Huri, H. Z., & Kamarul, T. (2016) · Cell Death & Disease · doi:10.1038/cddis.2015.275 · Cited by 279
Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes
Lombardi, P. M., Cole, K. E., Dowling, D. P., & Christianson, D. W. (2011) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2011.08.004 · Cited by 277
Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents
Licciardi, P., Ververis, Hiong, & Karagiannis (2013) · Biologics: Targets and Therapy · doi:10.2147/btt.s29965 · Cited by 274
Interplay between HDAC3 and WDR5 Is Essential for Hypoxia-Induced Epithelial-Mesenchymal Transition
Wu, M.-Z., Tsai, Y.-P., Yang, M.-H., Huang, C.-H., Chang, S.-Y., Chang, C.-C., Teng, S.-C., & Wu, K.-J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.07.012 · Cited by 273
A Systematic Review of miR-29 in Cancer
Kwon, J. J., Factora, T. D., Dey, S., & Kota, J. (2019) · Molecular Therapy Oncolytics · doi:10.1016/j.omto.2018.12.011 · Cited by 263
Li, L., & Li, W. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.01.004 · Cited by 254
Moreno, D. A., Scrideli, C. A., Cortez, M. A. A., De Paula Queiroz, R., Valera, E. T., Da Silva Silveira, V., Yunes, J. A., Brandalise, S. R., & Tone, L. G. (2010) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08301.x · Cited by 208
Halili, M. A., Andrews, M. R., Labzin, L. I., Schroder, K., Matthias, G., Cao, C., Lovelace, E., Reid, R. C., Le, G. T., Hume, D. A., et al. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0509363 · Cited by 186
Epigenetic alterations in autoimmune rheumatic diseases
Ballestar, E. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.16 · Cited by 173
Marek, M., Kannan, S., Hauser, A.-T., Moraes Mourão, M., Caby, S., Cura, V., Stolfa, D. A., Schmidtkunz, K., Lancelot, J., Andrade, L., et al. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003645 · Cited by 173
KAT5 tyrosine phosphorylation couples chromatin sensing to ATM signalling
Kaidi, A., & Jackson, S. P. (2013) · Nature · doi:10.1038/nature12201 · Cited by 167
RetractedSanders, Y. Y., Hagood, J. S., Liu, H., Zhang, W., Ambalavanan, N., & Thannickal, V. J. (2014) · European Respiratory Journal · doi:10.1183/09031936.00095113 · Cited by 167
Cole, K. E., Dowling, D. P., Boone, M. A., Phillips, A. J., & Christianson, D. W. (2011) · Journal of the American Chemical Society · doi:10.1021/ja205972n · Cited by 153
Histone deacetylase 3 as a novel therapeutic target in multiple myeloma
Minami, J., Suzuki, R., Mazitschek, R., Gorgun, G., Ghosh, B., Cirstea, D., Hu, Y., Mimura, N., Ohguchi, H., Cottini, F., et al. (2014) · Leukemia · doi:10.1038/leu.2013.231 · Cited by 159
Xia, C., Tao, Y., Li, M., Che, T., & Qu, J. (2020) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2020.9073 · Cited by 136
De Smaele, E., Di Marcotullio, L., Moretti, M., Pelloni, M., Occhione, M. A., Infante, P., Cucchi, D., Greco, A., Pietrosanti, L., Todorovic, J., et al. (2011) · Neoplasia · doi:10.1593/neo.101630 · Cited by 92
Interactions between epigenetics and metabolism in cancers
Yun, J., Johnson, J. L., Hanigan, C. L., & Locasale, J. W. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00163 · Cited by 82
Long, J., Jia, M.-Y., Fang, W.-Y., Chen, X.-J., Mu, L.-L., Wang, Z.-Y., Shen, Y., Xiang, R.-F., Wang, L.-N., Wang, L., et al. (2020) · Blood · doi:10.1182/blood.2019003538 · Cited by 84
Long, J., Fang, W. Y., Chang, L., Gao, W. H., Shen, Y., Jia, M. Y., Zhang, Y. X., Wang, Y., Dou, H. B., Zhang, W. J., et al. (2017) · Leukemia · doi:10.1038/leu.2017.130 · Cited by 78
Senescence-associated SIN3B promotes inflammation and pancreatic cancer progression
Rielland, M., Cantor, D. J., Graveline, R., Hajdu, C., Mara, L., de Diego Diaz, B., Miller, G., & David, G. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72619 · Cited by 76
TBX2 and TBX3: The special value for anticancer drug targets
Lu, J., Li, X.-P., Dong, Q., Kung, H.-F., & He, M.-L. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.07.001 · Cited by 57
Intlekofer, A. M., Joffe, E., Batlevi, C. L., Hilden, P., He, J., Seshan, V. E., Zelenetz, A. D., Palomba, M. L., Moskowitz, C. H., Portlock, C., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0089-0 · Cited by 35
Konsoula, Z., Cao, H., Velena, A., & Jung, M. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.11.057 · Cited by 27
Kong, Y., Ren, W., Fang, H., Shah, N. A., Shi, Y., You, D., Zhou, C., Jiang, D., Yang, C., Liang, H., et al. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.65322 · Cited by 25
Metadata
- Authors
- Lane, A. A., & Chabner, B. A.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-11-10
- Volume
- 27
- Issue
- 32
- Pages
- 5459-5468
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2102650381
- Cited by
- 874
- References
- 126
- FWCI
- 37.21
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.